Mesoblast (ASX:MSB) GF Score: 46/100 (As of Jun. 28, 2026) — Near Median


ASX:MSB Mesoblast Ltd ASX:MSB
46 GF Score
Price A$1.89
! 4 Warning Signs
View Full Analysis

What is Mesoblast GF Score?

Mesoblast ASX:MSB -9.38% 46 GF Score is 46 as of Jun. 28, 2026, which is 4% below its 10-year median of 48.00. GuruFocus rates ASX:MSB with a GF Score™ of 46/100. The stock has 4 warning signs investors should review.

Mesoblast has the GF Score of 46, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 5/10
2. Profitability Rank : 2/10
3. Growth Rank : 8/10
4. GF Value Rank : 2/10
5. Momentum Rank : 2/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Mesoblast might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Mesoblast  (ASX:MSB) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Mesoblast GF Score Related Terms

ASX:MSB vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Mesoblast's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mesoblast GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's GF Score distribution charts can be found below:

* The bar in red indicates where Mesoblast's GF Score falls into.


ASX:MSB
46GF Score
Mesoblast Ltd ASX:MSB
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 46 mean?
Mesoblast (ASX:MSB) has a GF Score of 46 as of Jun. 28, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Mesoblast and its competitors. This is near median its historical median of 48.00. Over the past decade, Mesoblast's GF Score has ranged from 26.00 to 71.00.
Is Mesoblast's GF Score too high?
Mesoblast's current GF Score of 46 is near median its 10-year median of 48.00. Over the past 10 years, this metric has ranged from a low of 26.00 to a high of 71.00. Overall, Mesoblast has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's GF Score compare to VRTX and REGN?
Mesoblast's GF Score of 46 can be compared against companies in the Biotechnology industry. Historically, Mesoblast's own GF Score has ranged from 26.00 to 71.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Mesoblast and its competitors. Mesoblast's current GF Score is 46, which is near median its own 10-year median of 48.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current GF Score of 46. The current GF Score is 46, which is near median its 10-year median of 48.00. Mesoblast's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current GF Score is 46 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
46GF Score

Get the complete analysis for ASX:MSB

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.89
Price